ORAPI |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.14 EUR | +3.02% |
|
-5.83% | -4.66% |
| 04-17 | Orapi SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-12 | Orapi: Groupe Paredes holds almost 90% of the capital | CF |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The stock, which is currently worth 2024 to 0.41 times its sales, is clearly overvalued in comparison with peers.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Commodity Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -4.66% | 41.45M | - | ||
| +5.14% | 103B | A- | ||
| -1.80% | 65.6B | A- | ||
| +39.52% | 39.06B | B | ||
| +12.91% | 37.58B | B | ||
| +7.32% | 33.26B | A- | ||
| +7.44% | 19.22B | B- | ||
| +12.86% | 16.83B | C+ | ||
| +7.73% | 15.03B | B | ||
| +16.93% | 14.96B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ORAP Stock
- Ratings ORAPI
